Unassociated Document
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C.  20549

Form 8-K

Current Report
Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934


Date of Report (Date of earliest event reported):  March 4, 2010
 
Renhuang Pharmaceuticals, Inc.
(Exact name of registrant as specified in its charter)


Nevada
(State or other
jurisdiction of incorporation)
  
O-24512
(Commission
File Number)
  
88-1273503
(I.R.S. Employer
Identification No.)
         
         
No. 281, Taiping Road, Taiping District,
Harbin, Heilongjiang Province, 150050
P. R. China
(Address of principal executive offices)  (zip code)
         
         
86-451-5762-0378
(Registrant’s telephone number, including area code)
         
         
 (Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

o
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
 
 
 
 
Item 7.01 Regulation FD Disclosure.

On March 4, Renhuang Pharmaceuticals Inc. (the “Company”) issued a press release to provide its 2010 guidance.  A copy of the press release is attached as Exhibit 99.1 to this report on Form 8-K.

On March 7, 2010, the Company will present at the Rodman & Renshaw Annual China Investment Conference to be held March 7-9 in Beijing, China. A copy of the Company’s presentation is attached as Exhibit 99.2 to this report on Form 8-K.

The information contained in this Current Report on Form 8-K and the exhibits attached hereto shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall such information or such exhibits be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing. The information set forth in or exhibits to this Form 8-K shall not be deemed an admission as to the materiality of any information in this report on Form 8-K that is required to be disclosed solely to satisfy the requirements of Regulation FD.

Item 9.01. Financial Statements and Exhibits.

(d)  Exhibits

Exhibits

99.1 Copy of Press Release of Rehuang Pharmaceuticals, Inc. dated March 4, 2010.
99.2 Copy of Company Presentation.
 
 
-2-
 
 
SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
 
Dated:  March 4, 2010
Renhuang Pharmaceuticals, Inc.
  
     
 
/s/ Shaoming Li 
  
 
Shaoming Li 
  
 
Chief Executive Officer 
  
 
 
-3-